Trials / Completed
CompletedNCT04352959
COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses
COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 176 (actual)
- Sponsor
- Claude Bernard University · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Given the current lack of effective COVID-19 treatment, it is necessary to explore alternative methods to contain the spread of the infection, focusing in particular on its mode of transmission. The modes of person-to-person transmission of SARS-CoV-2 are direct transmission, such as sneezing, coughing, transmission through inhalation of small droplets, and transmission through contact, such as contact with nasal, oral and eye mucous membranes. SARS-CoV-2 can also be transmitted directly or indirectly through saliva. The use of antiviral mouthrinses may be used as adjunctive therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | mouthrinse with bêta-cyclodextrin and citrox | 3 daily mouthrinses for 7 days |
| DEVICE | mouthrinse without bêta-cyclodextrin and citrox | 3 daily mouthrinses for 7 days |
Timeline
- Start date
- 2020-04-27
- Primary completion
- 2020-12-11
- Completion
- 2020-12-11
- First posted
- 2020-04-20
- Last updated
- 2021-02-11
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04352959. Inclusion in this directory is not an endorsement.